£1.7M
Owlstone Medical secures £1.7m from Cystic Fibrosis Foundation to develop a breath test for cystic fibrosis

The funding will support proof-of-principle work for detecting Pseudomonas aeruginosa infections in patients.
Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.
Announcements
503
Total raised
£3.8B
disclosed amounts
This month
£36.9M
raised so far

The funding will support proof-of-principle work for detecting Pseudomonas aeruginosa infections in patients.
Manchester United defender Diogo Dalot has backed the health supplement provider with over £841k.
"When it comes to high-level performance, my biggest focus has always been finding that extra 1% — the key to setting myself apart from the rest. Since discovering Bioniq in 2022, it’s been a game-changer for me. I’ve seen the results for myself. Achieving such progress is only possible with a product that’s truly personalized and tailored specifically to my needs. Now, I’m thrilled to take the next step as an investor. I believe in Bioniq’s mission and see the tremendous potential of this business, especially with the growing global demand for personalized nutrition."
The funding round was led by The FSE Group and included participation from the South West Investment Fund.
"We see too many people who are undergoing treatment or suffering from conditions, who don't understand what's going on, which increases their anxiety. It also increases the demands they make on their health systems and services around them. It's not fair, and it's not necessary."

The Series A round was led by IW Capital and will fund sales growth and product development.
"IW Capital are thrilled to announce our investment into Strolll. Strolll are transforming the physiotherapy and neurorehabilitation markets and have already helped a significant number of people with debilitating neurological disorders to live better lives. The potential impact of their software is huge and we’re proud to be backing this cutting-edge business as it addresses key healthcare needs."
The funding will support the design, manufacturing, and field trials of a non-antibiotic treatment for Helicobacter pylori.
"I’m excited by the possibility for this treatment to help a lot of people, benefiting their overall health and avoiding the misery of side effects from antibiotics."